Moderna (MRNA) Stock Forecast & Price Target

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

• Despite the recent stock surge, the consensus rating from analysts remains "Hold" with a median price target of $80.53 as of August 31, 2026, which is significantly lower than the current stock price of $194.82. This large discrepancy suggests that many analysts believe the stock is overvalued relative to its fundamental earnings potential. The negative P/E ratio of -24.38 further indicates that the company is still unprofitable, and the current valuation may not be supported by immediate financial performance, posing a risk of a significant correction if the stock fails to meet higher expectations.
• Insider selling activity has been consistent and substantial over the past six months, with 15 sales and no purchases reported. Key executives, including President Stephen Hoge and CFO James M Mock, have sold significant portions of their holdings, with Hoge selling over 240,000 shares for an estimated $20.6 million. While insider sales can be attributed to various personal financial reasons, a pattern of selling without corresponding buying can be interpreted as a lack of confidence in the stock's future performance or a desire to lock in gains, which may weigh on investor sentiment and limit upside potential.
• Moderna, Inc. continues to report negative earnings per share, with an actual EPS of -1.97 in the most recent quarter, although this was slightly better than the consensus estimate of -2.03. The company's inability to achieve profitability means that it is still burning cash, and investors must rely on future revenue growth and cost management to turn a profit. The negative P/E ratio of -24.38 highlights that the stock is priced based on growth expectations rather than current earnings, which can be risky if the company fails to execute on its pipeline or if the market environment becomes less favorable for high-growth biotech stocks.
• The company faces intense competition in the biotechnology sector, with other firms like Viking Therapeutics and Gilead Sciences also developing innovative therapies. While Moderna, Inc. has made significant strides in cancer vaccines, the competitive landscape is rapidly evolving, and the success of its products will depend on clinical trial results, regulatory approvals, and commercialization against established competitors. The high risk associated with biotech investments, where value can depend heavily on single clinical outcomes, means that any setbacks in the pipeline could lead to a sharp decline in the stock price, as seen in the volatility of the sector.
• Short interest in Moderna, Inc. has been a notable factor, with 32.8 million shares shorted as of September 15, 2026, representing about 9.23% of the float. Although the short interest has decreased slightly from previous months, the presence of a significant short position indicates that a portion of the market is betting against the stock. This can create volatility and pressure on the stock price, especially if the company fails to deliver on its promises or if broader market conditions turn negative. Investors should be aware that the stock is subject to potential short squeezes or continued selling pressure from bearish investors.